PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number 10/552,340 Filing Date October 6, 2005 First Named Inventor Toshihiro Yamamoto Art Unit N/A Examiner Name Not Yet Assigned Attorney Docket Number 64301(46590)

ENCLOSURES (Check all that apply)					
Fee Transi	mittal Form	Drawing(s)		After Allowance Communication to TC	
Fee Attached		Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences	
Amendme	nt/Reply	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
After	Final	Petition to Convert to a Provisional Application		Proprietary Information	
Affid	avits/declaration(s)	Power of Attorney, Revocation Change of Correspondence		Status Letter	
Extension	of Time Request	Terminal Disclaimer	ì	X Other Enclosure(s) (please Identify below):	
Express Al	bandonment Request			Return Receipt Postcard Copies of Cited References	
x Information	n Disclosure Statement	CD, Number of CD(s)			
Certified Copy of Priority Document(s)		Landscape Table on CD			
Reply to Missing Parts/ Incomplete Application		Remarks			
Reply to Missing Parts under				,	
				·	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm Name EDWARDS ANGELL PALMER & DODGE LLP					
Signature WWW Signature					
John Alexander, Ph.D.					
Date	January 6, 2006		Reg. No.	48,399	

5 pages, not including copies of citations

I hereby certify that this correspor in an envelope addressed to: MS	dence is being deposited with the U.S. Postal Service as Exp Amendment, Commissioner for Patents, P.O. Box 1450, Alex	oress Mail, Airbill No. EV756266153US, xandria, VA 22313-1450, on the date
shown below. Dated: January 6, 2006	Signature:	Latury saley)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV756266153US, in an envelope addressed to: MS Amendment, Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Signature:

Dated: January 6, 2006

Judy Dolow

Docket No.: 64301(46590) (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Toshihiro Yamamoto et al.

Application No.: 10/552,340

Confirmation No.: Not Yet

Assigned

Filed: October 6, 2005

Art Unit: N/A

For: SPECIFIC NAD(P)H OXIDASE INHIBITOR

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the U.S. filing date (37 CFR 1.97(b)(1)).

A summary/abstract translation of the non-English language references is enclosed.

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

Application No.: 10/552,340 2 Docket No.: 64301(46590)

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 64301(46590). A duplicate copy of this paper is enclosed.

Dated: January 6, 2006

Respectfully sulpmitted,

John B. Alexander, Ph.D.

Registration No.: 48,399

EDWARDS ANGELL PALMER & DODGE

LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	10/552,340	
	NFORMATION	N DI	SCLOSURE	Filing Date	October 6, 2005	
	STATEMENT I	3Y /	APPLICANT	First Named Inventor	Toshihiro Yamamoto	
				Art Unit	N/A	
	(Use as many sh	e ets as	necess ary)	Examiner Name	Not Yet Assigned	
Shee	t 1	of	1	Attorney Docket Number	64301(46590)	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	No.1	Number-Kind Code ² (if known)		Applicant of Cited Document	
	AA*	US-5,643,911-A		-	
	AB*	US-5,324,727-A			
	AC*	US-5,089,494-A			

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	₽°
	ВА	JP-10-109936-A		•		1
	BB	JP-2-129180-A				1
	ВС	JP-62-228067-A				1
	BD	WO-01/89517			,	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. 'Applicant's unique citation designation number (optional). *3 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	G. Cheng et al., Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5, Gene, 2001, 269(1-2), 131.	
	СВ	S. Shimohama et al., Activation of NADPH Oxidase in Alzheimer's Disease Brains, Biochem. Biophys. Res. Commun. 2000, 273(1), 5.	
	СС	S. DeAtley et al., Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture, Toxicology, 1999 May 3, 134(1): 51-62.	
	CD	T. Münzel et al., Evidence for Enhanced Vascular Superoxide Anion Production in Nitrate Tolerance, J. Clinical Investigation, 1995, 187-194.	
	CE	K. Griendling et al., NAD(P)H Oxidase Role in Cardiovascular Biology and Disease, Circ-Res. 2000, 86, 494-501.	
	CF	U. Bayraktutan et al., Expression of a functional neutrophil-type NADPH oxidase in cultured rat coronary microvascular endothelial cells, Cardiovascular Research, 1998, 38, 256-262.	
	CG	Y. Li et al., Diphenyleneiodonium, an NAD(P)H Oxidase Inhibitor, also Potently Inhibits Mitochondrial Reactive Oxygen Species Production, Biochem. Biophys. Res. Commun. 1998, 253, 295.	
	СН	A. Cayatte et al., S17834, a New Inhibitor of Cell Adhesion and Atherosclerosis that Targets NADPH Oxidase, Arterioscler. Thromb. Vasc. Biol., 2001, 21:1577.	
	CI	M. Geiszt et al., Chronic granulomatous disease: more than the lack of superoxide? J. Leukoc. Biol. 2001, 69, 191.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	



Application No. (if known): 10/552,340

Attorney Docket No.: 64301(46590)

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV756266153US in an envelope addressed to:

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on	January 6, 2006
	Date

Judy	Daley
Signature	0
Judy Dale	/
Typed or printed name of pers	on signing Certificate
	(617) 439-4444
Registration Number, if applicable	Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (16 References) (1 page)

Information Disclosure Statement (2 pages)
Transmittal (1 page)

Transmittal (1 page) Copies of Cited References Return Receipt Postcard